Lipella Pharmaceuticals, Inc. () Stock Analysis | Price, Returns, Financials & Key Metrics

Price Point

High/Low

1Day

52 Week

Valuation

Technical

Day's Volume

CASH

1.87 k

Shareholding (Mar 2025)

FII

0.00%

Held by 0 FIIs

DII

99.05%

Held by 1 DIIs

Promoter

0.00%

How big is Lipella Pharmaceuticals, Inc.?

22-Jun-2025

As of Jun 18, Lipella Pharmaceuticals, Inc. has a market capitalization of 12.08 million, with net sales of 0.52 million and a net profit of -5.13 million over the last four quarters. As of Dec'24, shareholder's funds were 1.92 million and total assets were 2.67 million.

What does Lipella Pharmaceuticals, Inc. do?

22-Jun-2025

Lipella Pharmaceuticals, Inc. is a micro-cap company in the Pharmaceuticals & Biotechnology industry, reporting net sales of $0 million and a net loss of $1 million as of March 2025, with a market cap of $12.08 million. Key financial metrics include a negative P/E ratio, a 0.00% dividend yield, and a return on equity of -125.78%.

Is Lipella Pharmaceuticals, Inc. technically bullish or bearish?

20-Sep-2025

As of September 2, 2025, Lipella Pharmaceuticals has a mildly bearish trend with mixed signals from indicators, showing a year-to-date decline of 79.02% compared to the S&P 500's 12.22% gain.

Score

Click here to find our call on this stock

Strong Sell

Sell

Hold

Buy

Strong Buy

MarketsMojo — Loved in India, Now Global

The power of Mojo is now in 29 countries. Explore global equities with the same cutting-edge features you love.Unlock 29 Markets

Dashboard

Unrated Stock - No Analysis Available

Mojo Parameters

Stock DNA

Industry

Pharmaceuticals & Biotechnology

Market cap

USD 3 Million ()

P/E

NA (Loss Making)

Industry P/E

Dividend Yield

0.00%

Debt Equity

-1.00

Return on Equity

-201.35%

Price to Book

0.99

Revenue and Profits:

Net Sales:

0 Million

(Quarterly Results - Jun 2025)

Net Profit:

-1 Million

Total Returns

Total Returns (Price + Dividend)

TimePeriod

Price Return

Dividend Return

Total Return

3 Months

-47.72%

6 Months

-89.45%

1 Year

-88.96%

2 Years

-96.64%

3 Years

0.0%

4 Years

0.0%

5 Years

0.0%

Lipella Pharmaceuticals, Inc. for the last several years.

Risk Adjusted Returns v/s

News & Corporate Actions

News

Is Lipella Pharmaceuticals, Inc. technically bullish or bearish?

As of 2 September 2025, the technical trend for Lipella Pharmaceuticals, Inc. has changed from bearish to mildly bearish. The weekly MACD and KST are both mildly bullish, while the RSI is bullish on both weekly and monthly time frames. However, the daily moving averages and Bollinger Bands indicate a bearish stance. Overall, the indicators suggest a mildly bearish outlook with some bullish signals present. The stock has underperformed significantly year-to-date, down 79.02% compared to the S&P 500's 12.22% return....

No announcement available

Corporate Actions

No corporate action available

Key Factors

Quality key factors

Factor

Value

Sales Growth (5y)

-79.19%

EBIT Growth (5y)

-156.03%

EBIT to Interest (avg)

-1.43

Debt to EBITDA (avg)

Negative Net Debt

Net Debt to Equity (avg)

-1.03

Sales to Capital Employed (avg)

0.19

Tax Ratio

Dividend Payout Ratio

Pledged Shares

Institutional Holding

8.17%

ROCE (avg)

ROE (avg)

Valuation key factors

Factor

Value

P/E Ratio

NA (Loss Making)

Industry P/E

Price to Book Value

3.27

EV to EBIT

-1.76

EV to EBITDA

-1.77

EV to Capital Employed

-9.16

EV to Sales

9.16

PEG Ratio

Dividend Yield

ROCE (Latest)

Negative Capital Employed

ROE (Latest)

-125.78%

Technicals key factors

Indicator

Weekly

Monthly

MACD

Mildly Bullish

Bearish

RSI

No Signal

Bullish

Bollinger Bands

Bearish

Moving Averages

Bearish (Daily)

KST

Mildly Bullish

Dow Theory

No Trend

Bearish

OBV

Mildly Bullish

Mildly Bearish

Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned

Shareholding

Shareholding Snapshot : Mar 2025

Shareholding Compare (%holding)

Majority shareholders

Domestic Funds

Held in 2 Schemes (0.95%)

Foreign Institutions

Held by 0 Foreign Institutions (0%)

Strategic Entities with highest holding

Highest Public shareholder

Financial

[
  {
    "link": "quarterly",
    "btn_text": "All Quarterly Results",
    "header": "Quarterly Results Snapshot (Consolidated) - Jun'25 - QoQ",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "QoQ Growth in quarter ended Jun 2025 is 0.00% vs -50.00% in Mar 2025",
        "dir": 1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "QoQ Growth in quarter ended Jun 2025 is 0.00% vs 7.14% in Mar 2025",
        "dir": -1
      }
    ],
    "table": {
      "header": [
        "Jun'25",
        "Mar'25",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "0.10",
          "val2": "0.10",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-1.40",
          "val2": "-1.30",
          "chgp": "-7.69%",
          "chgp_class": "negative"
        },
        {
          "field": "Interest",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-1.30",
          "val2": "-1.30",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "-15,641.90%",
          "val2": "-10,262.20%",
          "chgp": "-537.97%",
          "chgp_class": "negative"
        }
      ]
    }
  },
  {
    "link": "annual",
    "btn_text": "All Annual Results",
    "header": "Annual Results Snapshot (Consolidated) - Dec'24",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in year ended Dec 2024 is 25.00% vs 100.00% in Dec 2023",
        "dir": -1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in year ended Dec 2024 is -8.70% vs -76.92% in Dec 2023",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Dec'24",
        "Dec'23",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "0.50",
          "val2": "0.40",
          "chgp": "25.00%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-5.10",
          "val2": "-4.70",
          "chgp": "-8.51%",
          "chgp_class": "negative"
        },
        {
          "field": "Interest",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-5.00",
          "val2": "-4.60",
          "chgp": "-8.70%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "-9,472.30%",
          "val2": "-10,555.50%",
          "chgp": "108.32%",
          "chgp_class": "positive"
        }
      ]
    }
  }
]

Quarterly Results Snapshot (Consolidated) - Jun'25 - QoQ

Jun'25

Mar'25

Change(%)

Net Sales

0.10

Operating Profit (PBDIT) excl Other Income

-1.40

-1.30

-7.69%

Interest

0.00

Exceptional Items

0.00

Consolidate Net Profit

-1.30

Operating Profit Margin (Excl OI)

-15,641.90%

-10,262.20%

-537.97%

USD in Million.

Compare with Peers

Net Sales

QoQ Growth in quarter ended Jun 2025 is 0.00% vs -50.00% in Mar 2025

Consolidated Net Profit

QoQ Growth in quarter ended Jun 2025 is 0.00% vs 7.14% in Mar 2025

All Quarterly Results

Annual Results Snapshot (Consolidated) - Dec'24

Dec'24

Dec'23

Change(%)

Net Sales

0.50

0.40

25.00%

Operating Profit (PBDIT) excl Other Income

-5.10

-4.70

-8.51%

Interest

0.00

Exceptional Items

0.00

Consolidate Net Profit

-5.00

-4.60

-8.70%

Operating Profit Margin (Excl OI)

-9,472.30%

-10,555.50%

108.32%

USD in Million.

Compare with Peers

Net Sales

YoY Growth in year ended Dec 2024 is 25.00% vs 100.00% in Dec 2023

Consolidated Net Profit

YoY Growth in year ended Dec 2024 is -8.70% vs -76.92% in Dec 2023

All Annual Results

Company CV

About Lipella Pharmaceuticals, Inc.

Lipella Pharmaceuticals, Inc.

Pharmaceuticals & Biotechnology

No Details Available.

Company Coordinates

No Company Details Available

Lipella Pharmaceuticals, Inc.

1Day

52 Week

CASH

FII

DII

Promoter

How big is Lipella Pharmaceuticals, Inc.?

Watch in Real-Time

What does Lipella Pharmaceuticals, Inc. do?

Is Lipella Pharmaceuticals, Inc. technically bullish or bearish?

MarketsMojo — Loved in India, Now Global

Dashboard

Mojo Parameters

Stock DNA

Total Returns (Price + Dividend)

Risk Adjusted Returns v/s

News

Is Lipella Pharmaceuticals, Inc. technically bullish or bearish?

Announcements

Corporate Actions

Quality key factors

Valuation key factors

Technicals key factors

Shareholding Snapshot : Mar 2025

Shareholding Compare (%holding)

Quarterly Results Snapshot (Consolidated) - Jun'25 - QoQ

Annual Results Snapshot (Consolidated) - Dec'24

About Lipella Pharmaceuticals, Inc.

Company Coordinates